About Cubist Pharmaceuticals
Cubist Pharmaceuticals is a Healthcare company based in Lexington (United States) founded in 1993, and was acquired by Merck in December 2014. Pharmaceuticals for acute care bacterial infections are developed and commercialized. The company has 895 employees. Cubist Pharmaceuticals has completed 6 acquisitions, including Adolor, Calixa Therapeutics and Illumigen. Its chief executive, as recorded, is Ken Frazier. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Cubist Pharmaceuticals, Inc. Its competitors include Paratek Pharma, Spero Therapeutics and Cempra; 3 of its 3 listed competitors have raised funding.
Company details
As of Jan 2015, Cubist Pharmaceuticals operates as a subsidiary of Merck Co. Cubist Pharmaceuticals a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. It offers Cubicin (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; Dificid for the treatment of Clostridium difficile-associated diarrhea (CDAD); and Entereg (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozanetazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.
- Headquarters Lexington, United States
- Employees 895
- Stage Acquired
- SectorsHealthcare
- Website cubist.com
- Social LinkedIn
- Acquired by Merck (Dec 2014)
- Legal Name Cubist Pharmaceuticals, Inc
Investors in Cubist Pharmaceuticals
Cubist Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for Cubist Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cubist Pharmaceuticals
15 people are tracked at Cubist Pharmaceuticals (5 in leadership, 10 in team); the tracked headcount is 895.
| Name | Role | Group |
|---|---|---|
Ken Frazier | Chairman & CEO | Leadership |
Scott Rocklage | CEO | Leadership |
Michael Bonney | CEO | Leadership |
Karen Anderson | Chief Compliance Officer | Leadership |
Rob Clarke | Regional Business Director | Leadership |
Carmine Illiano | API Manufacturing Manager | Team |
Amy Torchia (Wu) | Sr. Manager, Quality Systems | Team |
Kevin Powers | Pharmaceutical Sales Representative | Team |
Michael Holmberg | Process Engineer I | Team |
Dana Carter | Clinical Business Manager | Team |
Laura Walsh | Senior Clinical Business Mng | Team |
Leah Simari | Executive Coordinator | Team |
Tameka Lord | Senior Clinical Business Manager | Team |
Joe Broders | Sr Clinical Business Manager | Team |
Thomas Lambert | Senior CBM | Team |
Complete people profiles for Cubist Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cubist Pharmaceuticals
Cubist Pharmaceuticals has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Adolor, Calixa Therapeutics and Illumigen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibiotics for serious infections are discovered, developed, and commercialized. | triusrx.com | San Diego, United States | 2004 | Jul 2013 | $704M | |
Biopharmaceutical research and development are conducted in San Diego. | optimerpharma.com | San Diego, United States | 1998 | Jul 2013 | $551M | |
Prescription pain and management products are developed and commercialized. | adolor.com | Exton, United States | 1993 | Oct 2011 | •••• | |
Development of a novel cephalosporin against the multi-drug resistant organisms | calixainc.com | San Mateo, United States | 2007 | Dec 2009 | $92.5M | |
Therapeutics for infectious diseases were developed by US-based Illumigen. | illumigen.com | Osaka, Japan | 2000 | Dec 2007 | $9M | |
Provider of diversified crop nutrition solutions for farmers | terragen.com | Richmond, United States | 2003 | Aug 2000 | $29M |
Complete acquisition details for Cubist Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Cubist Pharmaceuticals
8 dated milestones of Cubist Pharmaceuticals across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Cubist Pharmaceuticals is founded.
- Acquisition Acquires TerraGen.
- Acquisition Acquires Illumigen.
- Acquisition Acquires Calixa Therapeutics.
- Acquisition Acquires Adolor.
- Acquisition Acquires Trius Therapeutics.
- Acquisition Acquires Optimer Pharmaceuticals.
- Exit Acquired by Merck.
Competitors of Cubist Pharmaceuticals
Cubist Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Paratek Pharma, Spero Therapeutics and Cempra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials |
Detailed competitors of Cubist Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cubist Pharmaceuticals
Websites that share an audience with Cubist Pharmaceuticals (cubist.com).
Websites whose visitors overlap most with Cubist Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| optimerpharma.com | 100% | View details | |||
| chemocentryx.com | 98% | View details | |||
en.wikipedia.org | en.wikipedia.org | 96% | – | ||
| alkermes.com | 69% | 22.7K | #1,117,011 | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as Cubist Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cubist Pharmaceuticals
Complete news archive for Cubist Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cubist Pharmaceuticals
Cubist Pharmaceuticals was founded in 1993.
Cubist Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Ken Frazier is the CEO of Cubist Pharmaceuticals, as recorded in our data.
Cubist Pharmaceuticals has 895 employees.
As of Jan 2015, Cubist Pharmaceuticals operates as a subsidiary of Merck Co. Cubist Pharmaceuticals a biopharmaceutical company, is engaged in the research, development, and commercialization of pharmaceutical products for medical needs in the acute care environment in the United States. It offers Cubicin (daptomycin for injection), a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; Dificid for the treatment of Clostridium difficile-associated diarrhea (CDAD); and Entereg (alvimopan), an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also develops Tedizolid Phosphate, a novel antibiotic product candidate for the treatment of serious gram-positive bacterial infections; and Ceftolozanetazobactam, an I.V. antibacterial product candidate for the treatment of certain serious gram-negative bacterial infections in the hospital. In addition, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; and Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain.
Cubist Pharmaceuticals's top competitors include Spero Therapeutics, Paratek Pharma and Cempra.
Cubist Pharmaceuticals has made 6 acquisitions, including Adolor, Calixa Therapeutics, and Illumigen.
Cubist Pharmaceuticals has 1 investor. Key investors include Merck.
Cubist Pharmaceuticals operates through Cubist Pharmaceuticals, Inc.
Yes. Cubist Pharmaceuticals was acquired by Merck in December 2014.